Quantgene started in 2015 in a small UC Berkeley Lab under the leadership of Jo Bhakdi and Dr. Monika Hagen. Their theory was that most disease can be detected far earlier than today by introducing quantitative science and a new level of precision into medical practice.
Since then, the Quangene team has spent over 4 years building the industry’s best team of pioneers and developing the GRIFFIN Deep Genomics platform. GRIFFIN combines extreme precision sequencing, software and AI technologies to profile cell-free DNA (cfDNA) fragments with unprecedented depth and precision. In 2016, Quantgene launched its first clinical feasibility trial which continues today with the goal of adding 10,000 patient samples to the GRIFFIN platform by 2020.